SES Logo

SYSTEMIC ENZYME SUPPORT.org

 

Wobenzym in therapy of various forms of fibrocystic disease with individually selected immunomodulators.

Loginova N.S., Naumkina N.G., Sukhikh G.T. Wobenzym in therapy of various forms of fibrocystic disease with individually selected immunomodulators. International congress "Advances in Immunology and Allergology at the Treshold of the XXI Century" May 3-6, 2000, Eilat, Israel. Czech abstract Research Centre of Obstetrics, Gynecology and Perinatology, Moscow, Russia

Cancer of mammary glands is known to be registered 3-5 times more often in patients with fibrocystic disease (FCD), the risk increases 30 times as much in the signs of proliferation. We elaborated therapy regimen for patients with FCD by means of Wobenzym having antiinflammatory, immunomodulating effect. Immunomodulators were selected individually for every patient under the control of interferon status (IFS): Cycloferon, Ridostin, Polyoxidony. The treatment was performed in 36 women, aged from 23 to 52, having various forms of FCD: diffuse FCD: 1. multiple large filled cysts, 1.5-5.5 cm in diameter; 2. small cystic component prevailing; 3. glandular component prevailing. To assess the dynamic control of the quality of the therapy, we used radiothermometric method based on the measurement of internal temperature area (focal thermoassymetry).
Before the therapy, decreased abilities of lymphocytes to produce a -g -IFN had been noted, elevated level of serum IFN was found in blood. After the treatment, 87.3% patients had the restored ability of lymphocytes to produce a -g -IFN with the improved clinical picture, similar results were found in 23.4% of patients which underwent only basic therapy. Thus, Wobenzym is most efficient in combination with Cycloferon in the treatment of patients with mastopathy with small cystic, fibrous and glandular component prevailing.